The initial management decision in sustained monomorphic VT hinges on hemodynamic status. Hemodynamic instability (hypotension, altered consciousness, pulmonary edema, active ischemia) mandates immediate synchronized DC cardioversion regardless of drug therapy. In the hemodynamically stable patient, pharmacologic termination is reasonable as first-line.1
IV procainamide is the preferred pharmacologic agent for hemodynamically stable monomorphic VT in most current guidelines (Class IIa, ACC/AHA). Its Class Ia mechanism, intermediate-kinetics sodium channel blockade plus N-acetylprocainamide (NAPA)-mediated rapid delayed rectifier potassium current (IKr) blockade, terminates scar-mediated re-entrant VT by slowing conduction to the point of bidirectional block within the circuit.1,2 Dosing: 10–17 mg/kg IV at a maximum infusion rate of 50 mg/min (to minimize hypotension). Typical loading dose 1–1.5 g over 30–60 minutes. Stop criteria: Termination of VT; QRS widening ≥50% from baseline; hypotension (systolic BP fall >15 mmHg); total dose reached. Contraindications: Pre-existing QT prolongation (≥500 ms); significant LV dysfunction (negative inotropy and vasodilation risk); known procainamide hypersensitivity or prior drug-induced lupus erythematosus (DILE). Monitoring: Continuous ECG and blood pressure during infusion. Have atropine and vasopressors available.
IV amiodarone (150 mg over 10 minutes, then 1 mg/min for 6 hours) is guideline-supported for stable VT, particularly in patients with structural heart disease where procainamide's negative inotropy is a concern, or where VT is refractory to initial procainamide. Amiodarone's multi-channel profile (Classes I–IV) makes it effective across a broad range of VT substrates.1 It is less effective than procainamide for acute VT termination in head-to-head comparisons but carries less hemodynamic risk in severely impaired ventricles.
IV sotalol (1–1.5 mg/kg at 10 mg/min) is an alternative in stable VT, offering combined Class II/III activity. It is particularly useful in catecholamine-sensitive VT and in patients where beta-blockade is additionally desired. Caution in patients with baseline QT prolongation or renal impairment. Less commonly available as IV formulation outside specialist centers.2
Pulseless VT and VF are treated within the ACLS shockable rhythm algorithm. Pharmacologic therapy is adjunctive to defibrillation, drugs do not replace defibrillation but aim to improve defibrillation success and reduce recurrence.3
Epinephrine 1 mg IV every 3–5 minutes is the primary vasopressor in cardiac arrest. Its antiarrhythmic role is indirect: α1-mediated vasoconstriction increases coronary and cerebral perfusion pressure during CPR, improving the probability of successful defibrillation. β1-adrenergic stimulation increases myocardial excitability, which may facilitate defibrillation but can also increase post-resuscitation arrhythmia burden. The ROC PRIMED (Resuscitation Outcomes Consortium Prehospital Resuscitation using an IMpedance valve and Early versus Delayed analysis) and PARAMEDIC2 trials demonstrated survival to hospital discharge benefit from epinephrine but no improvement in neurologically favorable survival.3
The Amiodarone, Lidocaine, or Placebo Study (ALPS, 2016) randomized 3,026 patients with out-of-hospital VF or pulseless VT refractory to at least one shock to amiodarone (300 mg IV), lidocaine (1.5 mg/kg IV), or placebo. The primary endpoint was survival to hospital admission.4 Primary endpoint: Both amiodarone and lidocaine significantly improved survival to hospital admission compared to placebo (amiodarone 24.4%, lidocaine 23.7%, placebo 21.0%; p=0.04 for active drugs combined vs. placebo). Neurologically favorable survival to discharge: No significant difference between amiodarone, lidocaine, and placebo in the overall population. Bystander-witnessed arrest subgroup: Both active drugs showed a trend toward improved survival to discharge; this subgroup effect was not statistically significant but clinically noteworthy. Practical conclusion: Amiodarone and lidocaine have equivalent efficacy for shock-refractory VF/pVT. Both are superior to placebo for achieving ROSC. Amiodarone remains the guideline-preferred first-line agent; lidocaine is an acceptable alternative when amiodarone is unavailable.
ACLS Shockable Rhythm Algorithm: Drug Sequence
Shock → 2-min CPR → Check rhythm If VF/pVT persists after 2nd shock: Epinephrine 1 mg IV (repeat every 3–5 min) If VF/pVT persists after 3rd shock: Amiodarone 300 mg IV bolus (or lidocaine 1–1.5 mg/kg as alternative) Second amiodarone dose: 150 mg IV if VF/pVT recurs Treat reversible causes throughout (H’s and T’s) Post-ROSC: Initiate amiodarone infusion (1 mg/min × 6 hrs, then 0.5 mg/min × 18 hrs) if amiodarone used for termination
ICD implantation is the primary therapy for secondary prevention of SCD and for primary prevention in high-risk patients (EF ≤35%, NYHA Class II–III on optimal medical therapy). Antiarrhythmic drugs serve as adjuncts to reduce VT/VF burden, ICD shock frequency, and arrhythmic storm. Drugs do not replace the ICD but improve quality of life and reduce the adverse effects of repeated shocks.5
Beta-blockers are first-line adjunct therapy in all ICD recipients with structural heart disease. They reduce sympathetically triggered VT/VF, lower shock burden, and carry independent mortality benefit in heart failure with reduced ejection fraction (HFrEF). Maximally tolerated doses of carvedilol, metoprolol succinate, or bisoprolol should be targeted before adding other antiarrhythmics.5
The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial randomized 412 ICD patients to beta-blocker alone, sotalol, or amiodarone plus beta-blocker. At one year, shock rates were: amiodarone + beta-blocker 10.3%, sotalol 24.3%, beta-blocker alone 38.5%. Amiodarone plus beta-blocker was significantly superior to both comparators in reducing ICD shocks.6
However, amiodarone was associated with significantly more drug discontinuations due to toxicity (18.2% vs. 5.3% for sotalol vs. 5.8% for beta-blocker alone) at one year. This efficacy-toxicity tradeoff, amiodarone is most effective but least tolerated long-term, is the central pharmacologic tension in chronic VT management. Catheter ablation of the VT substrate is increasingly the preferred strategy to reduce shock burden while minimizing chronic amiodarone exposure.
Electrical storm (ES) is defined as three or more separate episodes of sustained VT or VF within 24 hours, each requiring intervention (ICD therapy or cardioversion). It is a life-threatening emergency with in-hospital mortality of 15–20%. The pharmacologic approach requires simultaneous rate/rhythm control and sympathetic suppression.7
IV amiodarone: 150 mg bolus over 10 minutes, then 1 mg/min infusion. Cornerstone of acute ES management. Multi-channel blockade addresses multiple arrhythmia mechanisms simultaneously. IV beta-blockade (sympathetic suppression): Mandatory and urgent. Catecholamine surge perpetuates ES through triggered activity and shortened refractory periods. IV metoprolol (5 mg boluses, repeat as tolerated) or IV esmolol infusion. This is the most underutilized intervention in ES management. Deep sedation also reduces catecholamine drive. IV magnesium sulfate:2 g IV bolus if polymorphic VT or torsades de pointes (TdP) pattern is present. Immediately excludes a drug-induced or electrolyte-mediated mechanism. Correct reversible triggers: Hypokalemia, hypomagnesemia, myocardial ischemia, metabolic derangement, and pro-arrhythmic drug changes must be identified and addressed urgently.
When ES persists despite IV amiodarone and beta-blockade, escalation options include:7,8
Deep sedation and intubation: Eliminates sympathetic activation from pain, anxiety, and ventilatory effort. General anesthesia (propofol or ketamine with opioid) may be required. Stellate ganglion block (SGB): Left SGB blocks sympathetic input to the heart via the stellate ganglion, reducing catecholamine-mediated arrhythmia triggers. Performed under ultrasound guidance. Case series report dramatic reduction in ES episodes. Right SGB may be considered in refractory cases. IV quinidine: In Brugada-related ES (where Ito blockade is specifically required), IV quinidine can suppress VF storms refractory to other agents. Emergent catheter ablation: VT substrate ablation during ongoing ES can be lifesaving when pharmacologic therapy fails, particularly in scar-mediated monomorphic VT. Mechanical circulatory support: IABP or VA-ECMO as bridge to definitive therapy when hemodynamic compromise accompanies refractory ES.
Inherited channelopathies — Brugada syndrome, long QT syndrome, and catecholaminergic polymorphic VT — require specific pharmacologic strategies that differ substantially from those for structural heart disease. Several commonly used antiarrhythmic and non-antiarrhythmic drugs are dangerous in these conditions.9
Brugada syndrome results from loss-of-function SCN5A mutations (or other genes encoding the cardiac sodium channel complex) reducing INa, creating heterogeneous phase 1 repolarization in the right ventricular outflow tract (RVOT). This produces the characteristic coved ST-elevation in V1–V3 and predisposes to VF via phase 2 re-entry.9 ICD: Only proven mortality-reducing therapy in symptomatic Brugada (prior VF or syncope with spontaneous type 1 pattern). Quinidine: Ito blockade normalizes the RVOT epicardial action potential notch, reducing the phase 2 re-entry substrate. Used for VF storm (IV), frequent ICD shocks, or in asymptomatic patients with inducible VF who decline ICD. Also
considered in infants with Brugada-related VF where ICD implantation is technically challenging. Isoproterenol (IV): Acute VF storm in Brugada, catecholamine stimulation increases L-type calcium current (ICaL) which counteracts the phase 2 re-entry mechanism. Used as a bridge to quinidine or ablation. Drugs to AVOID in Brugada: Sodium channel blockers (Class Ia: procainamide, ajmaline, used diagnostically but dangerous therapeutically; Class Ic: flecainide, propafenone), tricyclic antidepressants, cocaine, excessive alcohol, fever (unmasks pattern, treat promptly).
long QT syndrome (LQTS) is caused by mutations in genes encoding cardiac ion channels, producing delayed repolarization and QT prolongation. The three most common subtypes have distinct triggers and pharmacologic responses:9,10 LQT1 (KCNQ1, reduced slow delayed rectifier potassium current (IKs)) is triggered by exercise and swimming; beta-blockers are highly effective and nadolol or atenolol are preferred; avoid all QT-prolonging drugs and epinephrine. LQT2 (KCNH2/hERG, reduced IKr) is triggered by auditory stimuli, arousal, and emotional stress; beta-blockers are moderately effective and mexiletine may be used as an adjunct; avoid all IKr-blocking drugs and all QT-prolonging agents. LQT3 (SCN5A, increased late sodium current (INaL)) is triggered by rest, sleep, and bradycardia; mexiletine (INaL blockade) is the rational pharmacologic adjunct and pacing may be required for bradycardia; beta-blockers have limited efficacy; Class Ia and Ic agents and amiodarone should be avoided due to further sodium channel overlap.
As discussed in Part 3, CPVT management centers on maximal sympathetic suppression. Key pharmacologic principles in the context of VT/SCD prevention:9 Nadolol (first-line): Non-selective beta-blockade at the highest tolerated dose. Never discontinue abruptly. Flecainide (adjunct): Low-dose flecainide inhibits RyR2 directly, reducing SR Ca2+ leak independent of adrenergic tone. Added when nadolol alone is insufficient. ICD: For patients with prior cardiac arrest or recurrent syncope despite optimal medical therapy. Note: ICD shocks themselves cause sympathetic surges that can trigger further VF in CPVT; programming the ICD to deliver therapy only for sustained VF (rather than VT) and ensuring maximal beta-blockade is critical. Left cardiac sympathetic denervation (LCSD): Surgical or thoracoscopic removal of the left stellate ganglion and upper thoracic sympathetic ganglia. Reduces catecholamine release to the heart by ~70%. Considered in patients with breakthrough events on maximal medical therapy. Drugs That Unmask or Worsen Channelopathy Arrhythmias
BRUGADA: Sodium channel blockers (flecainide, procainamide, ajmaline), tricyclic antidepressants, cocaine, some antihistamines and psychotropics. Full list at brugadadrugs.org. LQTS: Any drug prolonging QTc — Class Ia/III antiarrhythmics, fluoroquinolones, macrolides, azole antifungals, antipsychotics, antiemetics (ondansetron, domperidone), methadone. Check CredibleMeds and the Arizona CERT (Center for Education and Research on Therapeutics) database before prescribing. CPVT: Avoid abrupt beta-blocker withdrawal. Avoid sympathomimetics (pseudoephedrine, high-dose bronchodilators). Use minimal stimulant medications.
Pharmacologic SCD prevention is secondary to ICD therapy in high-risk populations but remains the primary tool in patients who decline ICD, are ineligible, or require adjunctive arrhythmia suppression. The following principles summarize the evidence base:5,10,11
Beta-blockers: The only antiarrhythmic drug class with robust mortality benefit across multiple conditions, post-MI, HFrEF, CPVT, and LQTS type 1. First-line in all post-MI patients and all patients with EF ≤35%. Amiodarone: Reduces sudden cardiac death and VT recurrence in ICD recipients but does not improve total mortality in primary prevention. The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated that amiodarone did not improve survival vs. placebo in HFrEF patients, underscoring that ICD, not amiodarone, is the primary prevention tool. ACE inhibitors/ARBs and mineralocorticoid antagonists: Reduce sudden cardiac death by reversing adverse cardiac remodeling and preventing fibrosis, which is the substrate for re-entrant VT. These drugs are antiarrhythmic through upstream mechanism, not direct ion channel effects. Statin therapy: Associated with reduced VT/VF in observational studies in ICD populations, potentially through anti-inflammatory and anti-fibrotic mechanisms. Not an established antiarrhythmic indication but beneficial for underlying substrate.
The inherited channelopathies — Brugada syndrome, long QT syndrome, and catecholaminergic polymorphic ventricular tachycardia together account for a significant proportion of sudden cardiac death in patients without structural heart disease, particularly in the young. Each has a distinct ion channel defect, arrhythmia trigger, and pharmacologic approach. Detailed management principles are essential for appropriate prescribing and for recognizing drugs that are specifically contraindicated in each syndrome.
Brugada syndrome results from loss-of-function mutations in SCN5A encoding Nav1.5 (the cardiac fast sodium channel), reducing INa and creating heterogeneous phase 1 repolarization in the right ventricular outflow tract (RVOT). The resulting exaggerated Ito-mediated notch in RVOT epicardium but not endocardium generates a steep transmural voltage gradient that produces phase 2 re-entry: the action potential dome is lost in epicardial cells but maintained in endocardial cells, creating a re-entrant substrate that triggers VF.9
The diagnostic ECG pattern is a spontaneous or drug-provoked coved-type ST elevation of at least 2 mm in leads V1 through V3, which may be intermittent and concealed. Sodium channel blocking agents (ajmaline, flecainide, procainamide, and pilsicainide) unmask the pattern during diagnostic challenge testing by further reducing INa. This is also why these agents are specifically contraindicated therapeutically in Brugada syndrome: additional INa reduction worsens the phase 2 re-entry substrate.
Acute pharmacologic management of Brugada VF storm relies on isoproterenol as the bridge therapy. Isoproterenol activates beta-adrenergic receptors, increasing ICaL through PKA-mediated phosphorylation of Cav1.2. The increased ICaL restores the action potential dome in RVOT epicardial cells, eliminating the transmural voltage gradient driving phase 2 re-entry and suppressing VF recurrence. Isoproterenol infusion (1 to 4 mcg/min, titrated to heart rate 90 to 110 bpm) is the standard acute pharmacologic bridge until definitive therapy with quinidine or catheter ablation can be arranged.9
Quinidine is the preferred long-term pharmacologic option in Brugada syndrome. Its Ito blockade reduces the phase 1 notch in RVOT epicardium, attenuating the transmural voltage gradient. Quinidine is used as: an adjunct to ICD therapy to reduce shock frequency in patients with recurrent VF; a bridge to ICD in patients who are not yet implanted; and an alternative to ICD in asymptomatic Brugada patients with a high-risk EP study where patient preference or comorbidity disfavors ICD implantation. The QT-prolonging effect of quinidine requires ECG monitoring during initiation, though risk of torsades de pointes is lower in Brugada than in patients with normal ventricular repolarization.
Catheter ablation of the arrhythmic substrate in the RVOT epicardium has emerged as an effective treatment for VF storm in Brugada when pharmacologic management is insufficient, with case series demonstrating sustained VF suppression.
Long QT syndrome (LQTS) is a heterogeneous group of inherited repolarization disorders defined by QTc prolongation and susceptibility to early afterdepolarization (EAD)-mediated torsades de pointes. The three most common subtypes have distinct ion channel defects, arrhythmia triggers, and pharmacologic responses.
LQT1 is caused by loss-of-function mutations in KCNQ1, reducing IKs. The IKs current is the primary rate-adaptive repolarization reserve: during sympathetic activation, PKA-mediated phosphorylation of KCNQ1 normally increases IKs to shorten action potential duration (APD) at faster rates. In LQT1, this reserve is absent, so sympathetic stimulation causes paradoxical QT prolongation and EAD formation. Arrhythmias are characteristically triggered by exercise (particularly swimming) and sudden emotional stress. Beta-blockers are highly effective in LQT1, reducing syncopal events and sudden death by approximately 50 to 70% in symptomatic patients.8 Nadolol and atenolol are preferred for their long, consistent half-lives. Left cardiac sympathetic denervation (LCSD) is an effective non-pharmacologic adjunct for patients with breakthrough events on beta-blocker therapy. Sodium channel blockers and other QT-prolonging agents are contraindicated.
LQT2 is caused by loss-of-function mutations in KCNH2 (hERG), reducing IKr. IKr contributes substantially to phase 3 repolarization, and its reduction produces baseline QT prolongation that is sensitive to acute changes in sympathetic tone and to IKr-blocking drugs. Arrhythmias in LQT2 are characteristically triggered by sudden auditory stimuli (phone alarms, doorbells, loud sounds) and emotional arousal, mediated by acute sympathetic surges. Beta-blockers are moderately effective in LQT2, suppressing the sympathetic trigger, but less so than in LQT1 because the deficient IKr cannot be pharmacologically restored. Environmental modification (silencing alarm sounds, muting ringtones, using vibration alerts) specifically addresses the LQT2 trigger and should be counseled alongside pharmacologic therapy. Mexiletine may provide adjunctive benefit in LQT2 by shortening APD through late INa blockade.
LQT3 is caused by gain-of-function mutations in SCN5A, producing persistent late inward sodium current (INaL) that continuously depolarizes the cell during the action potential plateau, prolonging APD in a catecholamine-independent manner. Arrhythmias in LQT3 characteristically occur at rest or during sleep, when the slow heart rate maximizes APD prolongation through reverse use-dependence. Beta-blockers have limited efficacy in LQT3 because the arrhythmia mechanism is not sympathetically driven. Mexiletine, which blocks INaL selectively at therapeutic concentrations, is the rational pharmacologic adjunct in LQT3: it shortens the pathologically prolonged APD by reducing the sustained inward current sustaining it. The SCN5A mutation type predicts mexiletine responsiveness, and QTc shortening of 40 ms or more on mexiletine challenge is associated with clinical benefit. ICD implantation is strongly recommended in LQT3 given the limited beta-blocker efficacy and the frequent occurrence of arrhythmias during sleep when rate-based interventions are less reliable.8
CPVT, covered in detail in Section 3.4, warrants additional emphasis on escalation strategies and the pharmacologic rationale for combination therapy in refractory cases. The central mechanism, catecholamine-driven RyR2-mediated SR calcium leak generating DADs, provides multiple pharmacologic targets.
Flecainide at low doses (50 to 100 mg twice daily) directly stabilizes RyR2 through a mechanism independent of its sodium channel blocking activity, reducing spontaneous SR calcium release events that generate DADs. Multiple case series and the prospective cohort evidence support flecainide added to maximally tolerated beta-blockade in CPVT patients with breakthrough events. The combination of nadolol plus flecainide reduces the burden of exercise-induced ventricular arrhythmias more effectively than either agent alone in refractory CPVT. Verapamil has also been used as adjunctive therapy in CPVT on the rationale that ICaL blockade reduces calcium entry and SR loading, though evidence is less robust than for flecainide.
Left cardiac sympathetic denervation (LCSD) provides sustained arrhythmia reduction in CPVT patients refractory to optimal pharmacologic therapy by interrupting sympathetic innervation to the ventricle without removing the protective effects of reflex vagal activation. LCSD is not a substitute for ICD in high-risk patients but reduces shock burden. ICD implantation is indicated in CPVT patients who have survived cardiac arrest or who have sustained VT despite optimal pharmacologic therapy, recognizing that inappropriate ICD shocks can precipitate adrenergic surges that worsen VT storms.
The decision to implant an ICD versus to pursue pharmacologic management alone is one of the most consequential clinical decisions in cardiovascular medicine. The pharmacologic evidence informs both the appropriate selection of patients for ICD referral and the role of antiarrhythmic drugs as adjuncts to device therapy.
Secondary prevention of SCD refers to ICD implantation in patients who have survived a cardiac arrest or sustained VT with hemodynamic compromise. The AVID trial (1997) demonstrated that ICD therapy was superior to antiarrhythmic drug treatment (primarily amiodarone) for secondary prevention of life-threatening ventricular arrhythmias, reducing total mortality by 31% at 3 years. This trial established ICD implantation as the standard of care for secondary prevention, with antiarrhythmic drugs serving only as adjuncts to reduce device therapy burden.5
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT, 2005) is the pivotal primary prevention trial. SCD-HeFT randomized 2,521 patients with HFrEF (ejection fraction 35% or less, NYHA Class II or III) on optimal medical therapy to placebo, amiodarone, or a shock-only ICD. The ICD group had a significant 23% reduction in all-cause mortality compared to placebo. Amiodarone provided no mortality benefit compared to placebo and had a trend toward harm in NYHA Class III patients.5
The SCD-HeFT thresholds that define current primary prevention ICD eligibility are: ejection fraction 35% or less, NYHA Class II or III symptoms, and optimal guideline-directed medical therapy for at least 3 months. The 3-month waiting period is essential: beta-blockers and ACE inhibitors produce substantial reverse remodeling with EF improvement in many patients, and ICD implantation before this recovery period overestimates the true proportion of patients who remain below the 35% threshold long-term.
The Multicenter Automatic Defibrillator Implantation Trial II (MADIT II, 2002) randomized 1,232 patients with prior MI and ejection fraction 30% or less (regardless of symptoms or ambient arrhythmia) to ICD or conventional therapy. ICD therapy reduced all-cause mortality by 31% (relative risk 0.69; 95% CI 0.51 to 0.93). MADIT II extended primary prevention eligibility to the post-MI population with severely reduced EF without requiring NYHA symptom classification, though current guidelines integrate both MADIT II and SCD-HeFT criteria within the ejection fraction 35% or less NYHA Class II to III framework as the operative threshold.
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT, 2004) enrolled 674 patients with recent MI (within 6 to 40 days), ejection fraction below 35%, and impaired heart rate variability, randomized to ICD or no ICD. ICD implantation in the early post-MI period did not reduce total mortality, despite reducing arrhythmic death, because it was offset by an increase in non-arrhythmic cardiac deaths. This finding underlies the guideline recommendation to defer ICD evaluation for at least 40 days post-MI and for at least 3 months after revascularization, allowing time for optimal medical therapy and potential EF recovery before committing to device implantation.
SCD-HeFT definitively established that amiodarone does not provide primary prevention mortality benefit in HFrEF. This is a key clinical teaching point: the efficacy of amiodarone for terminating acute arrhythmias or reducing ICD shock frequency does not translate into primary prevention mortality benefit in patients with HFrEF who have not yet experienced a life-threatening event. Beta-blockers, ACE inhibitors, ARBs, sacubitril/valsartan, mineralocorticoid receptor antagonists, and SGLT2 inhibitors reduce SCD in HFrEF through neurohormonal modulation and reverse remodeling, not through direct antiarrhythmic mechanisms, and these agents are the pharmacologic foundation of primary prevention. Antiarrhythmic drugs are adjuncts to ICD therapy once the device indication threshold is met, not alternatives to it.
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793–2867
doi:10.1093/eurheartj/ehv316Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. Acad Emerg Med. 2010;17(3):297–306
doi:10.1111/j.1553-2712.2010.00680.xPanchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 Suppl 2):S366–S468
doi:10.1161/CIR.0000000000000916Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest (ALPS). N Engl J Med. 2016;374(18):1711–1722
doi:10.1056/NEJMoa1514204Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med. 2005;352(3):225–237
doi:10.1056/NEJMoa043399Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study. JAMA. 2006;295(2):165–171
doi:10.1001/jama.295.2.165Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. Tex Heart Inst J. 2011;38(2):111–121. PMID: 21494521
Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102(7):742–747
doi:10.1161/01.CIR.102.7.742Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):1932–1963
doi:10.1016/j.hrthm.2013.05.014Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88(2):782–784
doi:10.1161/01.CIR.88.2.782Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (MADIT II). N Engl J Med. 2002;346(12):877–883
doi:10.1056/NEJMoa013474